These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9444446)

  • 1. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
    Karch FE; Pordy R; Benz JR; Carr A; Lunde NM; Marbury T; Tarro JN
    Clin Ther; 1997; 19(6):1368-78. PubMed ID: 9444446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group.
    Viskoper RJ; Bernink PJ; Schelling A; Ribeiro AB; Kantola IM; Wilkins MR; Kobrin I
    J Hum Hypertens; 1997 Jun; 11(6):387-93. PubMed ID: 9249234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
    Bittar N
    Clin Ther; 1997; 19(5):954-62. PubMed ID: 9385483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
    Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
    Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J
    Clin Ther; 1996; 18(4):608-25. PubMed ID: 8879890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
    Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.
    Payeras AC; Sladek K; Lembo G; Alberici M
    Clin Drug Investig; 2007; 27(9):623-32. PubMed ID: 17705571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
    Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
    Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
    Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential properties of mibefradil in hypertension and angina.
    Kobrin I
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group.
    Zidek W; Spiecker C; Knaup G; Steindl L; Breuer HW
    Clin Ther; 1995; 17(4):686-700. PubMed ID: 8565032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
    Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
    Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect.
    Carney S; Wing L; Ribeiro A; Kallwellis R; Zimlichman R; Viskoper RJ; Mion D; Kobrin I
    J Hum Hypertens; 1997 Jul; 11(7):459-66. PubMed ID: 9283064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension.
    Chung O; Hinder M; Sharma AM; Bönner G; Middeke M; Platon J; Unger T
    Fundam Clin Pharmacol; 2000; 14(1):31-41. PubMed ID: 10681072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.